These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 25488176)

  • 1. Combined use of 18 F-FDG PET and corticosteroid for diagnosis of deep-seated primary central nervous system lymphoma without histopathological confirmation.
    Yamaguchi S; Hirata K; Kaneko S; Kobayashi H; Shiga T; Kobayashi K; Onimaru R; Shirato H; Tamaki N; Terasaka S; Houkin K
    Acta Neurochir (Wien); 2015 Feb; 157(2):187-94. PubMed ID: 25488176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The diagnostic role of (18)F-FDG PET for primary central nervous system lymphoma.
    Yamaguchi S; Hirata K; Kobayashi H; Shiga T; Manabe O; Kobayashi K; Motegi H; Terasaka S; Houkin K
    Ann Nucl Med; 2014 Aug; 28(7):603-9. PubMed ID: 24743915
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Zhou W; Wen J; Hua F; Xu W; Lu X; Yin B; Geng D; Guan Y
    Eur J Radiol; 2018 Jul; 104():26-32. PubMed ID: 29857862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Usefulness and limitation of FDG-PET in the diagnosis of primary central nervous system lymphoma].
    Kawai N; Miyake K; Okada M; Yamamoto Y; Nishiyama Y; Tamiya T
    No Shinkei Geka; 2013 Feb; 41(2):117-26. PubMed ID: 23378387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does adding FDG-PET to MRI improve the differentiation between primary cerebral lymphoma and glioblastoma? Observer performance study.
    Makino K; Hirai T; Nakamura H; Murakami R; Kitajima M; Shigematsu Y; Nakashima R; Shiraishi S; Uetani H; Iwashita K; Akter M; Yamashita Y; Kuratsu J
    Ann Nucl Med; 2011 Jul; 25(6):432-8. PubMed ID: 21404136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-FDG PET in the diagnosis and treatment of primary central nervous system lymphoma.
    Kawai N; Miyake K; Yamamoto Y; Nishiyama Y; Tamiya T
    Biomed Res Int; 2013; 2013():247152. PubMed ID: 23844359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differentiating between Primary Central Nervous System Lymphoma and Glioblastoma: The Diagnostic Value of Combining
    Hatakeyama J; Ono T; Takahashi M; Oda M; Shimizu H
    Neurol Med Chir (Tokyo); 2021 Jun; 61(6):367-375. PubMed ID: 33967177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18F-FDG PET/CT in primary brain lymphoma.
    Albano D; Bosio G; Bertoli M; Giubbini R; Bertagna F
    J Neurooncol; 2018 Feb; 136(3):577-583. PubMed ID: 29147860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative evaluation of
    Norikane T; Mitamura K; Yamamoto Y; Manabe Y; Murao M; Arai-Okuda H; Hatakeyama T; Miyake K; Nishiyama Y
    J Neurooncol; 2024 Jan; 166(1):195-201. PubMed ID: 38160415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic utility of intravoxel incoherent motion mr imaging in differentiating primary central nervous system lymphoma from glioblastoma multiforme.
    Yamashita K; Hiwatashi A; Togao O; Kikuchi K; Kitamura Y; Mizoguchi M; Yoshimoto K; Kuga D; Suzuki SO; Baba S; Isoda T; Iwaki T; Iihara K; Honda H
    J Magn Reson Imaging; 2016 Nov; 44(5):1256-1261. PubMed ID: 27093558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of tumor FDG transport and metabolism in primary central nervous system lymphoma using [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) kinetic analysis.
    Kawai N; Nishiyama Y; Miyake K; Tamiya T; Nagao S
    Ann Nucl Med; 2005 Dec; 19(8):685-90. PubMed ID: 16444994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative and Visual Characteristics of Primary Central Nervous System Lymphoma on
    Liu D; Kong Z; Wang Y; Chen W; Wang Y; Chen W; Liu L; Dang Y; Ma W; Wang Y; Cheng X
    Interdiscip Sci; 2019 Jun; 11(2):300-306. PubMed ID: 31264053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ¹⁸F-FDG PET/CT in HIV-related central nervous system pathology.
    Lewitschnig S; Gedela K; Toby M; Kulasegaram R; Nelson M; O'Doherty M; Cook GJ
    Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1420-7. PubMed ID: 23685752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of diagnostic performance of whole-body simultaneous PET/MRI in pediatric lymphoma.
    Ponisio MR; McConathy J; Laforest R; Khanna G
    Pediatr Radiol; 2016 Aug; 46(9):1258-68. PubMed ID: 27003132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary central nervous system lymphoma and glioblastoma: differentiation using dynamic susceptibility-contrast perfusion-weighted imaging, diffusion-weighted imaging, and (18)F-fluorodeoxyglucose positron emission tomography.
    Nakajima S; Okada T; Yamamoto A; Kanagaki M; Fushimi Y; Okada T; Arakawa Y; Takagi Y; Miyamoto S; Togashi K
    Clin Imaging; 2015; 39(3):390-5. PubMed ID: 25547624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of brain FDG-PET in primary CNS lymphoma.
    Mohile NA; Deangelis LM; Abrey LE
    Clin Adv Hematol Oncol; 2008 Nov; 6(11):818-20, 840. PubMed ID: 19194366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological characteristics of primary central nervous system lymphoma with low 18F-fludeoxyglucose uptake on brain positron emission tomography.
    Kim HO; Kim JS; Kim SO; Chae SY; Oh SJ; Seo M; Lee SH; Oh JS; Ryu JS; Huh JR; Kim JH
    Medicine (Baltimore); 2020 May; 99(20):e20140. PubMed ID: 32443328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prevalence and clinical significance of (18) F-2-fluoro-2-deoxy-D-glucose (FDG) uptake in the thyroid gland on PET or PET-CT in patients with lymphoma.
    Lin M; Wong C; Lin P; Shon IH; Cuganesan R; Som S
    Hematol Oncol; 2011 Jun; 29(2):67-74. PubMed ID: 20635328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up.
    Palmedo H; Urbach H; Bender H; Schlegel U; Schmidt-Wolf IG; Matthies A; Linnebank M; Joe A; Bucerius J; Biersack HJ; Pels H
    Eur J Nucl Med Mol Imaging; 2006 Feb; 33(2):164-8. PubMed ID: 16220304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of pretreatment 18F-FDG PET in patients with primary central nervous system lymphoma: SUV-based assessment.
    Kawai N; Zhen HN; Miyake K; Yamamaoto Y; Nishiyama Y; Tamiya T
    J Neurooncol; 2010 Nov; 100(2):225-32. PubMed ID: 20390437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.